FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036650948> ?p ?o ?g. }

• W3036650948 abstract "Abstract Background Ex vivo drug screening refers to the out-of-body assessment of drug efficacy in patient derived vital tumor cells. The purpose of these methods is to enable functional testing of patient specific efficacy of anti-cancer therapeutics and personalized treatment strategies. Such approaches could prove powerful especially in context of rare cancers for which demonstration of novel therapies is difficult due to the low numbers of patients. Here, we report comparison of different ex vivo drug screening methods in a metastatic urachal adenocarcinoma, a rare and aggressive non-urothelial bladder malignancy that arises from the remnant embryologic urachus in adults. Methods To compare the feasibility and results obtained with alternative ex vivo drug screening techniques, we used three different approaches; enzymatic cell viability assay of 2D cell cultures and image-based cytometry of 2D and 3D cell cultures in parallel. Vital tumor cells isolated from a biopsy obtained in context of a surgical debulking procedure were used for screening of 1160 drugs with the aim to evaluate patterns of efficacy in the urachal cancer cells. Results Dose response data from the enzymatic cell viability assay and the image-based assay of 2D cell cultures showed the best consistency. With 3D cell culture conditions, the proliferation rate of the tumor cells was slower and potency of several drugs was reduced even following growth rate normalization of the responses. MEK, mTOR, and MET inhibitors were identified as the most cytotoxic targeted drugs. Secondary validation analyses confirmed the efficacy of these drugs also with the new human urachal adenocarcinoma cell line (MISB18) established from the patient’s tumor. Conclusions All the tested ex vivo drug screening methods captured the patient’s tumor cells’ sensitivity to drugs that could be associated with the oncogenic KRAS G12V mutation found in the patient’s tumor cells. Specific drug classes however resulted in differential dose response profiles dependent on the used cell culture method indicating that the choice of assay could bias results from ex vivo drug screening assays for selected drug classes." @default.
• W3036650948 created "2020-06-25" @default.
• W3036650948 creator A5013962943 @default.
• W3036650948 creator A5026844879 @default.
• W3036650948 creator A5027928097 @default.
• W3036650948 creator A5030000724 @default.
• W3036650948 creator A5030385925 @default.
• W3036650948 creator A5031247308 @default.
• W3036650948 creator A5031424976 @default.
• W3036650948 creator A5035141841 @default.
• W3036650948 creator A5054345295 @default.
• W3036650948 creator A5062191415 @default.
• W3036650948 date "2020-06-23" @default.
• W3036650948 modified "2023-10-17" @default.
• W3036650948 title "Ex vivo modelling of drug efficacy in a rare metastatic urachal carcinoma" @default.
• W3036650948 cites W1606972930 @default.
• W3036650948 cites W1782443628 @default.
• W3036650948 cites W1968358301 @default.
• W3036650948 cites W1992790404 @default.
• W3036650948 cites W2032454374 @default.
• W3036650948 cites W2053066993 @default.
• W3036650948 cites W2065628014 @default.
• W3036650948 cites W2066712926 @default.
• W3036650948 cites W2074884346 @default.
• W3036650948 cites W2083438251 @default.
• W3036650948 cites W2096439168 @default.
• W3036650948 cites W2114005284 @default.
• W3036650948 cites W2122321442 @default.
• W3036650948 cites W2266707907 @default.
• W3036650948 cites W2302618494 @default.
• W3036650948 cites W2364154657 @default.
• W3036650948 cites W2411596490 @default.
• W3036650948 cites W2414613644 @default.
• W3036650948 cites W2417825232 @default.
• W3036650948 cites W2514830499 @default.
• W3036650948 cites W2576619896 @default.
• W3036650948 cites W2601380465 @default.
• W3036650948 cites W2608911462 @default.
• W3036650948 cites W2751798174 @default.
• W3036650948 cites W2769605488 @default.
• W3036650948 cites W2770026599 @default.
• W3036650948 cites W2799394815 @default.
• W3036650948 cites W2807968682 @default.
• W3036650948 cites W2808350668 @default.
• W3036650948 cites W2934342832 @default.
• W3036650948 cites W2954971215 @default.
• W3036650948 cites W2959521790 @default.
• W3036650948 cites W2970636464 @default.
• W3036650948 cites W2985508900 @default.
• W3036650948 cites W2993566291 @default.
• W3036650948 cites W2998568935 @default.
• W3036650948 cites W3000124456 @default.
• W3036650948 cites W3022408452 @default.
• W3036650948 doi "https://doi.org/10.1186/s12885-020-07092-w" @default.
• W3036650948 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7313172" @default.
• W3036650948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32576176" @default.
• W3036650948 hasPublicationYear "2020" @default.
• W3036650948 type Work @default.
• W3036650948 sameAs 3036650948 @default.
• W3036650948 citedByCount "5" @default.
• W3036650948 countsByYear W30366509482021 @default.
• W3036650948 countsByYear W30366509482022 @default.
• W3036650948 countsByYear W30366509482023 @default.
• W3036650948 crossrefType "journal-article" @default.
• W3036650948 hasAuthorship W3036650948A5013962943 @default.
• W3036650948 hasAuthorship W3036650948A5026844879 @default.
• W3036650948 hasAuthorship W3036650948A5027928097 @default.
• W3036650948 hasAuthorship W3036650948A5030000724 @default.
• W3036650948 hasAuthorship W3036650948A5030385925 @default.
• W3036650948 hasAuthorship W3036650948A5031247308 @default.
• W3036650948 hasAuthorship W3036650948A5031424976 @default.
• W3036650948 hasAuthorship W3036650948A5035141841 @default.
• W3036650948 hasAuthorship W3036650948A5054345295 @default.
• W3036650948 hasAuthorship W3036650948A5062191415 @default.
• W3036650948 hasBestOaLocation W30366509481 @default.
• W3036650948 hasConcept C121608353 @default.
• W3036650948 hasConcept C126322002 @default.
• W3036650948 hasConcept C142724271 @default.
• W3036650948 hasConcept C143998085 @default.
• W3036650948 hasConcept C150903083 @default.
• W3036650948 hasConcept C151730666 @default.
• W3036650948 hasConcept C207001950 @default.
• W3036650948 hasConcept C26291073 @default.
• W3036650948 hasConcept C2779343474 @default.
• W3036650948 hasConcept C2780427987 @default.
• W3036650948 hasConcept C2781100745 @default.
• W3036650948 hasConcept C502942594 @default.
• W3036650948 hasConcept C71924100 @default.
• W3036650948 hasConcept C86803240 @default.
• W3036650948 hasConcept C98274493 @default.
• W3036650948 hasConceptScore W3036650948C121608353 @default.
• W3036650948 hasConceptScore W3036650948C126322002 @default.
• W3036650948 hasConceptScore W3036650948C142724271 @default.
• W3036650948 hasConceptScore W3036650948C143998085 @default.
• W3036650948 hasConceptScore W3036650948C150903083 @default.
• W3036650948 hasConceptScore W3036650948C151730666 @default.
• W3036650948 hasConceptScore W3036650948C207001950 @default.
• W3036650948 hasConceptScore W3036650948C26291073 @default.
• W3036650948 hasConceptScore W3036650948C2779343474 @default.
• W3036650948 hasConceptScore W3036650948C2780427987 @default.

• next